A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients

Endostatin may predict mortality and kidney impairment in general populations as well as in critically ill patients. We decided to explore the possible role of endostatin as a predictor of 30-day mortality, acute kidney injury (AKI), and renal replacement therapy (RRT) in a cohort of unselected inte...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Toralph Ruge, Anders Larsson, Miklós Lipcsey, Jonas Tydén, Joakim Johansson, Mats Eriksson
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	acute kidney injury critical illness endostatin epidemiology intensive care unit mortality Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/d5522bcbbf0e4e03a6d8e2a7889f8211
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d5522bcbbf0e4e03a6d8e2a7889f8211
record_format	dspace
spelling	oai:doaj.org-article:d5522bcbbf0e4e03a6d8e2a7889f82112021-11-25T16:49:31ZA Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients10.3390/biomedicines91116032227-9059https://doaj.org/article/d5522bcbbf0e4e03a6d8e2a7889f82112021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1603https://doaj.org/toc/2227-9059Endostatin may predict mortality and kidney impairment in general populations as well as in critically ill patients. We decided to explore the possible role of endostatin as a predictor of 30-day mortality, acute kidney injury (AKI), and renal replacement therapy (RRT) in a cohort of unselected intensive care unit (ICU) patients. Endostatin and creatinine in plasma were analyzed and SAPS3 was determined in 278 patients on ICU arrival at admission to a Swedish medium-sized hospital. SAPS3 had the highest predictive value, 0.85 (95% C.I.: 0.8–0.90), for 30-day mortality. Endostatin, in combination with age, predicted 30-day mortality by 0.76 (95% C.I.: 0.70–0.82). Endostatin, together with age and creatinine, predicted AKI with 0.87 (95% C.I.: 0.83–0.91). Endostatin predicted AKI with [0.68 (0.62–0.74)]. Endostatin predicted RRT, either alone [0.82 (95% C.I.: 0.72–0.91)] or together with age [0.81 (95% C.I.: 0.71–0.91)]. The predicted risk for 30-day mortality, AKI, or RRT during the ICU stay, predicted by plasma endostatin, was not influenced by age. Compared to the complex severity score SAPS3, circulating endostatin, combined with age, offers an easily managed option to predict 30-day mortality. Additionally, circulating endostatin combined with creatinine was closely associated with AKI development.Toralph RugeAnders LarssonMiklós LipcseyJonas TydénJoakim JohanssonMats ErikssonMDPI AGarticleacute kidney injurycritical illnessendostatinepidemiologyintensive care unitmortalityBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1603, p 1603 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute kidney injury critical illness endostatin epidemiology intensive care unit mortality Biology (General) QH301-705.5
spellingShingle	acute kidney injury critical illness endostatin epidemiology intensive care unit mortality Biology (General) QH301-705.5 Toralph Ruge Anders Larsson Miklós Lipcsey Jonas Tydén Joakim Johansson Mats Eriksson A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients
description	Endostatin may predict mortality and kidney impairment in general populations as well as in critically ill patients. We decided to explore the possible role of endostatin as a predictor of 30-day mortality, acute kidney injury (AKI), and renal replacement therapy (RRT) in a cohort of unselected intensive care unit (ICU) patients. Endostatin and creatinine in plasma were analyzed and SAPS3 was determined in 278 patients on ICU arrival at admission to a Swedish medium-sized hospital. SAPS3 had the highest predictive value, 0.85 (95% C.I.: 0.8–0.90), for 30-day mortality. Endostatin, in combination with age, predicted 30-day mortality by 0.76 (95% C.I.: 0.70–0.82). Endostatin, together with age and creatinine, predicted AKI with 0.87 (95% C.I.: 0.83–0.91). Endostatin predicted AKI with [0.68 (0.62–0.74)]. Endostatin predicted RRT, either alone [0.82 (95% C.I.: 0.72–0.91)] or together with age [0.81 (95% C.I.: 0.71–0.91)]. The predicted risk for 30-day mortality, AKI, or RRT during the ICU stay, predicted by plasma endostatin, was not influenced by age. Compared to the complex severity score SAPS3, circulating endostatin, combined with age, offers an easily managed option to predict 30-day mortality. Additionally, circulating endostatin combined with creatinine was closely associated with AKI development.
format	article
author	Toralph Ruge Anders Larsson Miklós Lipcsey Jonas Tydén Joakim Johansson Mats Eriksson
author_facet	Toralph Ruge Anders Larsson Miklós Lipcsey Jonas Tydén Joakim Johansson Mats Eriksson
author_sort	Toralph Ruge
title	A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients
title_short	A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients
title_full	A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients
title_fullStr	A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients
title_full_unstemmed	A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients
title_sort	comparison between endostatin and conventional biomarkers on 30-day mortality and renal replacement therapy in unselected intensive care patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d5522bcbbf0e4e03a6d8e2a7889f8211
work_keys_str_mv	AT toralphruge acomparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT anderslarsson acomparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT mikloslipcsey acomparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT jonastyden acomparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT joakimjohansson acomparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT matseriksson acomparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT toralphruge comparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT anderslarsson comparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT mikloslipcsey comparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT jonastyden comparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT joakimjohansson comparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients AT matseriksson comparisonbetweenendostatinandconventionalbiomarkerson30daymortalityandrenalreplacementtherapyinunselectedintensivecarepatients
_version_	1718412927098159104

A Comparison between Endostatin and Conventional Biomarkers on 30-Day Mortality and Renal Replacement Therapy in Unselected Intensive Care Patients

Ejemplares similares